A Comprehensive Analysis of the Downregulation of miRNA-1827 and Its Prognostic Significance by Targeting SPTBN2 and BCL2L1 in Ovarian Cancer

Feng, Penghui; Ge, Zhitong; Guo, Zaixin; Lin, Lin; Yu, Qi

doi:10.3389/fmolb.2021.687576

Cited by 10 publications

(14 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…What’s more, SPTBN2 was associated with poor prognosis in patients with colorectal cancer and was highly expressed in patients with distant metastasis, lymph node metastasis, and clinical advanced colorectal cancer, with statistically significant differences [ 8 ]. In recent studies, it has been confirmed that the mRNA and protein levels of SPTBN2 were upregulated in ovarian cancer, and which was involved in a variety of biological processes associated with tumorigenesis and was highly associated with poor prognosis of ovarian cancer [ 9 ]. In our study, we found SPTBN2 was significantly upregulated in human UCEC for the first time, and the high expression of SPTBN2 was related to poor prognosis, suggesting that SPTBN2 can be served as a powerful predictor of UCEC prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…As a protein-coding gene, the protein products of SPTBN2 belong to the Spectrin family. Studies have shown that SPTBN2 is up-regulated in MPNST [ 7 ], colorectal cancer [ 8 ], and ovarian cancer [ 9 ],which was involved in a variety of biological processes related to tumorigenesis. SPTBN2 has been identified as one of the marker genes for the pathogenesis of cancer and plays an important role in the pathogenesis of cancer, which is of great significance for understanding the pathogenesis and early diagnosis of cancer [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SPTBN2 regulated by miR-424-5p promotes endometrial cancer progression via CLDN4/PI3K/AKT axis

et al. 2021

View full text Add to dashboard Cite

Endometrioid Endometrial Cancer (EEC) is the main subtype of endometrial cancer. In our study, we demonstrated that SPTBN2 was significantly overexpressed in EEC tissues. Upregulated SPTBN2 expression was positively associated with poor prognosis. In addition, we testified that SPTBN2 knockdown significantly inhibited the proliferation, migration, and invasion of EEC cells. Moreover, we found SPTBN2 could interact with CLDN4 to promote endometrial cancer metastasis via PI3K/AKT pathway. Then we further demonstrated that CLDN4 is upregulated in EEC and promotes EEC metastasis. CLDN4 overexpression could partially reversed the decrease in cell migration and invasion caused by SPTBN2 downregulation. In addition, we confirmed that SPTBN2 was a target of miR-424-5p, which plays a tumor suppressor in endometrial cancer. Rescue experiments showed that inhibition of SPTBN2 could partially reverse the effect of miR-424-5p in EEC. In conclusion, we demonstrated that by acting as a significant target of miR-424-5p, SPTBN2 could interact with CLDN4 to promote endometrial cancer metastasis via PI3K/AKT pathway in EEC. Our study revealed the prognostic and metastatic effects of SPTBN2 in EEC, suggesting that SPTBN2 could serve as a prognostic biomarker and a target for metastasis therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

SPTBN2 regulated by miR-424-5p promotes endometrial cancer progression via CLDN4/PI3K/AKT axis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A growing body of evidence has extensively proven that SPTBN2 plays a vital role in the diagnosis of cholangiocarcinoma. For example, by using a bioinformatics approach, Feng et al demonstrated that SPTBN2 is highly associated with poor prognosis in ovarian cancer [ 25 ]. Zhang et al and Yue et al reported that SPTBN2 may play a vital role in the progression of colorectal cancer [ 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

SPTBN2 Promotes the Progression of Thyroid Cancer by Accelerating G1/S Transition and Inhibiting Apoptosis

Zhou

Lin

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Background. Thyroid carcinoma (TC) is an increasingly common malignancy of endocrine organs, and its most frequently encountered histotype is papillary thyroid cancer (PTC). Identifying new potential gene alterations is important for completely elucidating the mechanism of PTC initiation and progression. Thus, we performed whole transcriptome sequence analysis (RNA-seq) on 79 PTC tissue samples and paired adjacent nontumor tissue samples to study the molecular mechanism of TC tumorigenesis and progression further. The results of RNA-seq analysis showed that spectrin beta, nonerythrocytic 2 (SPTBN2), was markedly overexpressed in PTC tissues relative to that in the paired nontumor tissues. Additionally, the analysis results for 502 PTC samples and 58 nontumor thyroid samples from The Cancer Genome Atlas dataset were consistent with our RNA-seq results. However, the molecular mechanisms and function of SPTBN2 in TC progression remain unknown. Methods. We examined SPTBN2 gene expression in 48 papillary thyroid tumor tissues and paired adjacent normal thyroid tissues by using qRT-PCR. SPTBN2 expression in the TC cell lines was silenced by small interfering RNA. Then, the transfected TC cells were used to investigate the in vitro function of SPTBN2. Result. The expression of SPTBN2 was significantly upregulated in our RNA-seq cohort, our local validated cohort, and TCGA RNA-seq cohort. The results of the in vitro experiment revealed that in TC cell lines, SPTBN2 downregulation considerably suppressed tumor cell proliferation, the cell cycle, migration, colony formation, and invasion and induced cell apoptosis. Furthermore, the protein levels of CCNE2, CDK2, CDK4, and Bcl-2 were downregulated, and those of P21, Bax, cleaved caspase-8, and cleaved caspase-3 had increased in transfected TC cells relative to in control TC cells. Conclusion. The downregulation of SPTBN2 caused apoptosis and retarded G1/S cell cycle transition in TC cells. Thus, SPTBN2 may be a good candidate gene for TC diagnosis and therapy.

show abstract

“…This gene mutation can lead to spinocerebellar ataxia ( Yıldız et al, 2017 ). In ovarian cancer, the upregulation of SPTBN2 has been associated with poor prognosis ( Feng et al, 2021 ). TIMP1, tissue inhibitor matrix metalloproteinase-1, belongs to the tissue inhibitor of metalloproteinases family.…”

Section: Discussionmentioning

confidence: 99%

An Apoptosis-Related Gene Prognostic Index for Colon Cancer

Tang

Wang

Luo

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Purpose: To construct an apoptosis-related gene prognostic index (ARGPI) for colon cancer, and clarify the molecular and immune characteristics of the risk subgroup as defined by the prognostic index and the benefits of adjuvant chemotherapy. Integrating the prognostic index and clinicopathological risk factors to better evaluate the prognosis of patients with colon cancer.Methods: Based on the colon adenocarcinoma data in the TCGA database, 20 apoptosis-related hub genes were screened by weighted gene co-expression network analysis (WGCNA). Five genes constituting the prognosis model were determined by Cox regression and verified by the Gene Expression Omnibus (GEO) dataset. Then the molecular and immune characteristics of risk subgroups defined by the prognostic index and the benefits of adjuvant chemotherapy were analyzed. Finally, nomograms integrating ARGPI and four clinicopathological risk factors were used to evaluate the prognosis of patients with colon cancer.Results: The ARGPI was constructed based on the FAS, VWA5A, SPTBN2, PCK1, and TIMP1 genes. In the TCGA cohort, patients in the low-risk subgroup had a longer progression-free interval (PFI) than patients in the high-risk subgroup, which coincided with the results of the GEO cohort. The comprehensive results showed that the high-risk score was related to the enrichment of the cell cycle pathway, high mutation rate of TP53 and KRAS, high infiltration of T regulatory cells (Tregs), immunosuppressive state, and less chemotherapeutic benefit. However, low-risk scores are related to drug metabolism-related pathways, low TP53 and KRAS mutation rates, high infiltration of plasma cells, more resting CD4 memory cells and eosinophils, active immune function, and better chemotherapeutic benefits. Receiver operating characteristic curve of two-year progress prediction evaluation showed that the ARGPI had higher prognostic accuracy than TNM staging. Nomograms integrating ARGPI and clinicopathological risk factors can better evaluate the prognosis of patients with colon cancer.Conclusions: The ARGPI is a promising biomarker for determining risk of colon cancer progression, molecular and immune characteristics, and chemotherapeutic benefit. This is a reliable method to predict the prognosis of colon cancer patients. It also can assist doctors in formulating more effective treatment strategies.

show abstract

A Comprehensive Analysis of the Downregulation of miRNA-1827 and Its Prognostic Significance by Targeting SPTBN2 and BCL2L1 in Ovarian Cancer

Cited by 10 publications

References 66 publications

SPTBN2 regulated by miR-424-5p promotes endometrial cancer progression via CLDN4/PI3K/AKT axis

SPTBN2 regulated by miR-424-5p promotes endometrial cancer progression via CLDN4/PI3K/AKT axis

SPTBN2 Promotes the Progression of Thyroid Cancer by Accelerating G1/S Transition and Inhibiting Apoptosis

An Apoptosis-Related Gene Prognostic Index for Colon Cancer

Contact Info

Product

Resources

About